If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlkemy Capital. Regulatory News (ALK)

Share Price Information for Alkemy Capital. (ALK)

Share Price is delayed by 15 minutes
Get Live Data
240.00    10.00 (4.35%)
Bid:
236.00
Ask:
245.00
Spread: 9.00 (3.814%)
Market Cap: £26.72m
ALK Live PriceLast checked at - London Stock Exchange

Intraday Alkemy Capital. Share Chart

Grant of Options

4 Aug 2022 08:00

RNS Number : 8525U
Alkemy Capital Investments PLC
04 August 2022
 

 

4 August 2022

 

Alkemy Capital Investments Plc

Grant of Options

 

Alkemy Capital Investments plc ("Alkemy") (LSE: ALK) is pleased to announce that further to its announcement earlier today it has granted 590,000 share options at £1 per share, for a period of 5 years, to further align Directors and senior management with shareholders.

The share options will vest one-third immediately, one-third following completion of construction finance for train 1 of TVL's processing facility in Teesside, and one-third following commissioning of train 1 of TVL's processing facility.

In addition the share options will only be exerciseable if the share price of the Company is in excess of £5 per share for 10 consecutive days.

The grant of share options to directors is set out below:

Options

Exercise Price

Term

Paul Atherley (Chairman)

175,000

£1.00

5 years

Sam Quinn (Director)

140,000

£1.00

5 years

Helen Pein (Director)

75,000

£1.00

5 years

 

Further information

For further information, please visit the Company's website: www.alkemycapital.co.uk or www.teesvalleylithium.co.uk

-Ends-

Alkemy Capital Investments Plc

Sam Quinn

Tel: 0207 317 0636

info@alkemycapital.co.uk

Buchanan

Bobby Morse/Abigail Gilchrist

Tel: 0207 466 5000

TVL@buchanan.uk.com

VSA Capital Limited

Andrew Monk (corporate broking)

Andrew Raca (corporate finance)

Tel: 0203 005 5000

amonk@vsacapital.com

araca@vsacapital.com 

Shard Capital Partners LLP

Damon Heath

 

Isabella Pierre

 

Tel: 0207 186 9952

damon.heath@shardcapital.com

Tel: 0207 186 9927

isabella.pierre@shardcapital.com

 

NOTES TO EDITORS

Alkemy is seeking to develop, construct and operate the world's leading independent and sustainable lithium hydroxide production facility.

Alkemy, through its wholly-owned subsidiary Tees Valley Lithium, has secured exclusivity to negotiate an option to lease over a 9.6ha brownfields site at the Wilton International Chemicals Park located in Teesside, a major UK Freeport.

Alkemy has completed a Class 4 Feasibility Study for its proposed lithium hydroxide facility to process feedstock imported from various sources to produce 96,000 tonnes of premium, low-carbon lithium hydroxide annually, representing around 15% of Europe's projected demand.

 

 

Forward Looking Statements

This news release contains forward‐looking information. The statements are based on reasonable assumptions and expectations of management and Alkemy provides no assurance that actual events will meet management's expectations. In certain cases, forward‐looking information may be identified by such terms as "anticipates", "believes", "could", "estimates", "expects", "may", "shall", "will", or "would". Although Alkemy believes the expectations expressed in such forward‐looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those projected. In addition, factors that could cause actual events to differ materially from the forward-looking information stated herein include any factors which affect decisions as to how to develop the project, process the materials and exercise the options in respect of the lease, which may include changes in market conditions, changes in metal prices, general economic and political conditions, environmental risks, and community and non-governmental actions. Such factors will also affect whether Alkemy will ultimately receive the benefits anticipated pursuant to relevant agreements. This list is not exhaustive of the factors that may affect any of the forward‐looking statements. These and other factors should be considered carefully and readers should not place undue reliance on forward-looking information.

 

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

1. Paul Atherley

2. Sam Quinn

3. Helen Pein

 

2

 

Reason for the notification

a)

 

Position/status

 

1. Chairman

2. Director

3. Director

 

b)

 

Initial notification /Amendment

 

Intial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Alkemy Capital Investments PLC

b)

 

LEI

 

213800NW5GVIRMXSRL48

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares

Identification code

GB00BMD6C023

b)

 

Nature of the transaction

 

Grant of Share Options subject to vesting conditions and only be exerciseable if the share price of the Company's ordinary shares is in excess of £5 per share for 10 consecutive days.

c)

 

Price(s) and volume(s)

Excersie Price(s)

Volume(s)

1. 1.00

2. 1.00

3. 1.00

 

175,000

140,000

75,000

 

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

£1.00

e)

 

Date of the transaction

 

03/08/2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBCGDIDUGDGDX
Date   Source Headline
8th Jul 20262:20 pmRNSTVL and E3 Lithium Refining Partnership
3rd Jul 20262:11 pmRNSResult of AGM
15th Jun 20267:01 amRNSTees Valley Lithium: Publication of Impact Report
15th Jun 20267:00 amRNSIssue of Shares
10th Jun 20267:00 amRNSNotice of AGM
28th May 20267:00 amRNSAnnual Report & Financial Statements
24th Apr 20267:00 amRNSTVL Project Development Update
19th Mar 20267:00 amRNSTVL Industry Engagement Update
27th Feb 20263:00 pmRNSLoan Conversion
24th Feb 20267:00 amRNSTVL Appoints Wates group
12th Feb 20267:00 amRNSTVL Advances On-Site Lithium Recovery
5th Feb 20263:26 pmRNSGrant of Share Awards
3rd Feb 20267:00 amRNSTVL FEED Study
29th Jan 20264:07 pmRNSLoan Conversion
28th Jan 20269:35 amRNSTVL and Glencore Sign Binding Offtake Agreement
14th Jan 20267:00 amRNSTVL FEED Study Update
9th Dec 202511:40 amRNSLoan Conversion
27th Nov 20253:00 pmRNSExercise of Warrants and Loan Conversion
10th Nov 20257:00 amRNSTees Valley Lithium Financing and Project Delivery
5th Nov 20257:00 amRNSAppointment of ABG Sundal Collier ASA
3rd Nov 20251:28 pmRNSExercise of Warrants
29th Oct 20254:23 pmRNSExercise of Warrants
15th Oct 20257:00 amRNSInterim Results
9th Oct 20257:00 amRNSTVL: Appointment of COO & Launch of OEP
6th Oct 20257:00 amRNSTVL: Lower CAPEX, Higher Uptime, Stronger Outlook
29th Aug 20257:00 amRNSTVL Project and Leadership Update
31st Jul 20253:00 pmRNSExercise of Warrants
31st Jul 20257:00 amRNSFEED Funding and Equity Funding Proposal
17th Jul 20257:00 amRNSTVL Secures Binding Feedstock Agreement
25th Jun 20257:00 amRNSOversubscribed Subscription to raise £500,000
18th Jun 20251:00 pmRNSResult of AGM
2nd Jun 20257:05 amRNSAlkemy Shareholder Call
2nd Jun 20257:00 amRNSTVL Update: Process Validated, CAPEX Confirmed
23rd May 20253:00 pmRNSNotice of AGM
21st May 20254:30 pmRNSFinal Results
12th May 20257:05 amRNS-RAlkemy Shareholder Call
12th May 20257:00 amRNSExclusivity Agreement Signed with Ara Partners
18th Mar 20257:00 amRNSTVL - Exclusive Negotiation for Lithium Supply
18th Feb 20257:00 amRNSTVL Appoints New CEO and Commences FEED Study
17th Feb 20258:27 amRNSReplacement: Subscription to raise £0.75 million
17th Feb 20257:00 amRNSPlacing to raise £1.035 million
31st Jan 20257:00 amRNSTVL Collaborates with Veolia
6th Nov 20247:00 amRNSChairman Share Purchases
24th Oct 20248:00 amRNSABG Sundal Collier to lead US$25m Convertible Bond
2nd Oct 20247:00 amRNSInterim Results
5th Aug 20247:00 amRNSCorporate Update
2nd Jul 20242:00 pmRNSResult of AGM
5th Jun 20244:30 pmRNSNotice of AGM
30th May 20244:30 pmRNSAnnual Report & Financial Statements
26th Feb 20247:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.